Screener
Arcus Biosciences RCUS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(219) | $(112) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 34 | 31 |
| Depreciation and amortization | 5 | 5 |
| Noncash lease expense | 4 | 3 |
| Amortization of discounts on marketable securities | (5) | (7) |
| Other items, net | 2 | — |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's stock-based comp?
- Arcus Biosciences (RCUS) reported stock-based comp of $15M in Q2 2026.
- How has Arcus Biosciences's stock-based comp changed year-over-year?
- Arcus Biosciences's stock-based comp decreased by 0.0% year-over-year, from $15M to $15M.
- What is the long-term trend for Arcus Biosciences's stock-based comp?
- Over 4 years (2021 to 2025), Arcus Biosciences's stock-based comp has grown at a 2.2% compound annual growth rate (CAGR), from $55M to $60M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Arcus Biosciences's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude